ArticleMedicina oral, patologia oral y cirugia bucal2012
Expression of semaphorin 3A and neuropilin 1 with clinicopathological features and survival in human tongue cancer.
Article in Medicina oral, patologia oral y cirugia bucal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- Influences of Semaphorin 3A Expression on Clinicopathological Features, Human Papillomavirus Status, and Prognosis in Oropharyngeal Carcinoma.Microorganisms · 2020Article
- Neuropilin-1 is associated with the prognosis of cervical cancer in Henan Chinese population.OncoTargets and therapy · 2019Article
- New and Old Genes Associated with Primary and Established Responses to Paclitaxel Treatment in Ovarian Cancer Cell Lines.Molecules (Basel, Switzerland) · 2018Article
- Prognostic and clinicopathological value of melanoma-associated antigen D4 in patients with glioma.Oncology letters · 2018Article
- Neuropilin-1 contributes to esophageal squamous cancer progression via promoting P65-dependent cell proliferation.Oncogene · 2018Article
- Sema3A drastically suppresses tumor growth in oral cancer Xenograft model of mice.BMC pharmacology & toxicology · 2017Article
- Nomograms to estimate long-term overall survival and tongue cancer-specific survival of patients with tongue squamous cell carcinoma.Cancer medicine · 2017Article
- The role of the semaphorins in cancer.Cell adhesion & migration · 2016Review
- Use of NRP1, a novel biomarker, along with VEGF-C, VEGFR-3, CCR7 and SEMA3E, to predict lymph node metastasis in squamous cell carcinoma of the tongue.Oncology reports · 2016Article
- 14-3-3ζ silencing retards tongue squamous cell carcinoma progression by inhibiting cell survival and migration.Cancer gene therapy · 2016Article
- Neuropilin 1 Receptor Is Up-Regulated in Dysplastic Epithelium and Oral Squamous Cell Carcinoma.The American journal of pathology · 2016Article
- Axon guidance molecule semaphorin3A is a novel tumor suppressor in head and neck squamous cell carcinoma.Oncotarget · 2016Article
- Neuropilin-1 is overexpressed in osteosarcoma and contributes to tumor progression and poor prognosis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2014Article
- The emerging role of class-3 semaphorins and their neuropilin receptors in oncology.OncoTargets and therapy · 2014Review
- Decreased expression of SEMA3A is associated with poor prognosis in gastric carcinoma.International journal of clinical and experimental pathology · 2014Article
- Article
- Neuroimmune semaphorin 4A as a drug and drug target for asthma.International immunopharmacology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the association between semaphorin 3A (SEMA 3A) and its receptor neuropilin 1 (NRP1) and the clinicopathologic characteristics of patients with tongue cancer. STUDY
designForty-three tongue squamous cell carcinoma specimens were included. Immunohistochemical staining of SEMA3A and NRP1 was performed on 15 normal tongue epithelium specimens and the 43 tumour specimens. Immunoreactivity was evaluated based on the staining intensity and distribution score. Statistical analyses were performed using Chi-squared and Spearman tests and Kaplan-Meier analysis.
resultsSEMA3A was significantly down-regulated in tongue cancer compared with normal tongue (P=0.025), while NRP1 was over-expressed in tumours (P<0.001). SEMA3A expression inversely correlated with nodal metastasis (P=0.017). NRP1 expression did not correlate with any clinicopathological characteristics. Higher SEMA3A expression strongly predicted longer survival (P=0.005). Scores for the NRP1/SEMA3A ratio of ≥1 predicted shorter survival (P=0.045).
conclusionsAberrant expression of SEMA3A and its receptor NRP1 might be involved in the development of tongue cancer and might be useful prognostic markers in this tumour type.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.